



Newsletter from Emotra AB (publ)

Göteborg, November 14, 2018

Emotra: Successful meetings with psychiatric hospitals

Emotra has recently held a number of meetings with decision-makers who intend to move forward with testing of EDOR® in their regular clinical practice. The psychiatric caregivers that Emotra has met this autumn have grown increasingly aware of how EDOR test results can supplement the diagnoses they make in their clinical examinations. They see the value of starting the process of using the method as a supplement to their risk assessments of depressed patients.

During Emotra's discussions with psychiatric hospitals in London and Paris this autumn, caregivers have stated that they understand the value of testing with EDOR as a supplement to their traditional processes. An EDOR test provides information about a biologically based risk factor, which is an important supplement to the psychologically and socially based risk factors that are checked in connection with the clinical examination of a patient.

They now want to try Emotra's method on a limited scale to determine how they in practice would organise such testing, manage the analysis results, as well as how they could best apply this technology in their patient care workflows. Their goal is to gain some initial experience and then evaluate how it affects their organisation, communication and patient care before they move on to the next step. It is important to point out that these evaluations concern controlled implementations in clinical practice; they do not concern the performance of clinical studies.

Emotra's CEO, Daniel Poté, has the following comments on these developments

"Since we embarked on our commercialisation phase in the middle of January, we have been forced to modify and clarify our communication with a continued focus. We are still on the learning curve since we are pioneering a completely new market on our own. The fact that we, in such a short period of time, have come so far in the process with these hospitals is a victory in itself, and will support us in our continued marketing efforts."

As we have previously stated, Emotra's strategy is to focus its marketing efforts on major metropolitan areas in Europe, which seems to be working well for us. We are now planning training sessions similar in design to the one we recently carried out in Germany, while at the same time reviewing our testing management and capacity.

For further information, please contact: Daniel Poté, CEO, telephone: +46 732 34 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.